BBLG

Bone BiologicsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$2.20

+73.2% vs current

Most likely

Base case

45%

Probability

Target price

$0.90

-29.1% vs current

B-

Bear case

35%

Probability

Target price

$0.35

-72.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

BBLG remains a cautious monitoring name, not a standard-conviction long. Primary-source evidence supports the financing and program-status discussion, but the peer set is weak and should not be treated as validating valuation or operating momentum. The deterministic prior is negative, and the most tangible dated hook is still financing/runway management rather than a near-term clinical readout. That keeps sentiment tentative and low-conviction [#10-K-2026-03-02] [#8-K-2026-03-13].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-06-30catalystATM issuance overhang remains activeHigh impact

A March 13, 2026 8-K disclosed a prospectus supplement for sales of up to $1.064 million of common stock under the existing ATM program, after roughly $1.7 million had already been sold under the sales agreement; for a ~$2.8 million market-cap issuer, incremental use of this facility is a near-term supply overhang even if it helps liquidity [#8-K-2026-03-13].

2026-10-01eventRunway versus financing decision into Q4 2026High impact

The 2026-03-02 10-K said cash was $5.33 million at December 31, 2025, operating expenditures for the next twelve months were estimated at $4.9 million, and available cash was expected to fund operations into the fourth quarter of 2026, keeping a financing/runway checkpoint squarely in focus [#10-K-2026-03-02].

2026-12-31catalystNB1 pilot enrollment and IDE-enabling progressHigh impact

The 10-K says the first-in-man Australia pilot for NB1 had its first subject enrolled in 2024, is designed for up to 30 subjects, and management anticipates submitting an IDE about 12 months after enrolling the 30th subject; any credible enrollment progress or data maturation would be the main fundamental upside driver, but timing remains uncertain [#10-K-2026-03-02].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology